Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals logo
$0.39 +0.01 (+3.56%)
As of 03:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Key Stats

Today's Range
$0.38
$0.40
50-Day Range
$0.34
$1.12
52-Week Range
$0.30
$4.28
Volume
2.80 million shs
Average Volume
1.37 million shs
Market Capitalization
$18.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Reviva Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

RVPH MarketRank™: 

Reviva Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 595th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Reviva Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Reviva Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Reviva Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Reviva Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Reviva Pharmaceuticals has a P/B Ratio of 19.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Reviva Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.11% of the float of Reviva Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently increased by 4.88%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Reviva Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Reviva Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.11% of the float of Reviva Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently increased by 4.88%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    16 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Reviva Pharmaceuticals' insider trading history.
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Reviva Dives on Stock Offering
See More Headlines

RVPH Stock Analysis - Frequently Asked Questions

Reviva Pharmaceuticals' stock was trading at $1.81 at the start of the year. Since then, RVPH stock has decreased by 78.5% and is now trading at $0.39.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.08.

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
5/15/2025
Today
7/09/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVPH
CIK
1742927
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$3.00
Potential Upside/Downside
+2,289.8%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.92 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
18.83

Miscellaneous

Free Float
34,957,000
Market Cap
$18.08 million
Optionable
Optionable
Beta
-0.06
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RVPH) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners